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PMF. Although the number of patients was small, one ofrimary myeloﬁbrosis (PMF) is a clonal hematopoietic disorder
haracterized by an initial preﬁbrotic proliferative phase that
ver time progresses to bone marrow ﬁbrosis, extramedullary
ematopoiesis, peripheral blood cytopenias and an increased
isk of developing acute myeloid leukemia (AML). In recent
ears, the molecular mechanisms that cause PMF have been
xtensively studied and the genomic changes that cause the
isease have been widely elucidated.1
A unique feature of PMF  is a systemic inﬂammatory
eaction that manifests, among other things, through high
erum levels of inﬂammatory cytokines and chemokines,
nd a stromal bone marrow reaction involving collagen
eposition and increased vascular proliferation.2,3 There
s now convincing evidence that megakaryocytes play a
ajor role in this stromal reaction.4,5 More speciﬁcally,
egakaryocytes from patients with PMF  produce high levels
f inﬂammatory cytokines including transforming growth
actor-beta 1 (TGF1).6 Recently, PMF  systemic inﬂammatory
eaction has taken center stage after a suggestion that
 possible mechanism by which ruxolitinib, a JAK1 and
AK2 inhibitor, increases overall survival, is through its
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eserved.anti-inﬂammatory effect, as this medication only marginally
decreases the disease burden.7
While the diagnosis of advanced PMF is not a major
challenge, the differential diagnosis between preﬁbrotic PMF
and essential thrombocythemia (ET), a related neoplastic
disease, is not always easy,8 since both diseases are
characterized by high platelet counts, increased bone marrow
cellularity, and increased number of atypical megakaryocytes
in the bone marrow. The importance of making such
differentiation is fundamental, since most patients with ET
have a benign disease while PMF patients have a substantial
decrease in overall survival.9,10
In this issue of the Revista Brasileira de Hematologia e
Hemoterapia (RBHH), Ponce et al. evaluated the expression of
anti-latency-associated peptide (LAP) human TGF1 in bone
marrow megakaryocytes as well as the microvascular density
(MVD) in bone marrow biopsies from patients with ET and
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the main ﬁndings of the study was that MVD  is signiﬁcantly
increased in preﬁbrotic PMF  compared to ET. Since there is
no objective way of histologically differentiating preﬁbrotic
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PMF  from ET, the addition of a novel diagnostic tool that may
contribute to this differentiation is welcomed. If the ﬁnding
of increased MVD  observed predominantly in patients with
preﬁbrotic PMF  in this study can be reproduced by other
authors, it could serve as another diagnostic marker, with the
potential to improve the pathologist’s ability to differentiate
between these two conditions. Recently, immunostaining for
nuclear factor, erythroid-derived 2 (NF-E2) on bone marrow
biopsies has shown to be a promising technique to help
differentiate between preﬁbrotic PMF  and ET.12
Another ﬁnding of the study of Ponce et al. was
the relationship between megakaryocyte TGF1 expression,
MVD  and bone marrow ﬁbrosis, suggesting a possible
mechanism by which increased levels of TGF1 produced by
megakaryocytes can induce an inﬂammatory reaction that
culminates in new vessel formation and ﬁbrosis.11 Although
no causal relationship can be determined, this ﬁnding adds to
the literature, pointing to a role for TGF1 on the process of
neo-angiogenesis and ﬁbrosis in human and animal models
of PMF.6,13
In conclusion, these ﬁndings may contribute to improve
our ability to differentiate patients with preﬁbrotic PMF and ET
and also reafﬁrms a possible role of TGF1 in neo-angiogenesis
in PMF.
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